07:00 , May 7, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Phosphodiesterase 3B, cGMP-inhibited (PDE3B); caveolin 3 (CAV3)

Cardiovascular disease INDICATION: Myocardial infarction (MI) In vitro and mouse studies suggest inhibiting PDE3B could help treat MI. In a mouse model of cardiac ischemia/reperfusion injury, cardiac-specific knockout of PDE3B decreased infarct size, increased levels...